Nivolumab

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, PD-L1, PCR, Bristol Myers Squibb, NYSE, EFS, Checkmate, Nivolumab, BMY, NSCLC, Patient, MPR, Pharmaceutical industry

Neoadjuvant Opdivo with chemotherapy also showed improvements in pathologic complete response (pCR) and major pathologic response (MPR) over chemotherapy alone in PD-L1 ≥1% and

Key Points: 
  • Neoadjuvant Opdivo with chemotherapy also showed improvements in pathologic complete response (pCR) and major pathologic response (MPR) over chemotherapy alone in PD-L1 ≥1% and
  • pCR: In patients with PD-L1 ≥1%, pCR rates were 32.6% with neoadjuvant Opdivo with chemotherapy compared to 2.2% with chemotherapy alone.
  • MPR: Among patients with PD-L1 ≥1%, MPR rates with neoadjuvant Opdivo with chemotherapy were 44.9% vs. 5.6% with chemotherapy.
  • Definitive Surgery: Definitive surgery rates with Opdivo with chemotherapy vs. chemotherapy were 84% vs. 74% in patients with tumor PD-L1 expression ≥1% and 81% vs. 77% in patients with tumor PD-L1 expression

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial

Retrieved on: 
Tuesday, October 17, 2023
Surgery, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Congress, Confidence interval, Physician, NYSE, Lung cancer, Bristol Myers Squibb, Hope, Death, Research, Abstract, Disclosure, Risk, Disease, MD Anderson Cancer Center, European Society for Medical Oncology, Cancer, ESMO, University, Melanoma, EFS, IIA, Checkmate, EDT, Bladder cancer, Overalls, PCR, BMY, Patient, MPR, Pharmaceutical industry, NSCLC, Nivolumab

Additionally, neoadjuvant Opdivo and chemotherapy showed improvements in the secondary efficacy endpoints of pathologic complete response (pCR; 25.3% vs. 4.7%) and major pathologic response (MPR; 35.4% vs 12.1%).

Key Points: 
  • Additionally, neoadjuvant Opdivo and chemotherapy showed improvements in the secondary efficacy endpoints of pathologic complete response (pCR; 25.3% vs. 4.7%) and major pathologic response (MPR; 35.4% vs 12.1%).
  • Definitive surgery rates were 78% with the Opdivo-based regimen vs. 77% with chemotherapy and placebo, with complete resection achieved in 89% vs. 90% of patients, respectively.
  • “Over the past few years, we have witnessed incredible progress in the treatment of patients with non-metastatic non-small cell lung cancer.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -77T clinical trial.

Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress

Retrieved on: 
Monday, October 16, 2023
Congress, Adrenal tumor, Gustave Roussy, Oncology, ESMO, Nivolumab, Associate, European Society for Medical Oncology, Inflammation, Patient, Pharmaceutical industry, Canning, Villejuif

PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 , to take place on October 20-23, 2023 in Madrid, Spain.

Key Points: 
  • PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 , to take place on October 20-23, 2023 in Madrid, Spain.
  • Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Retrieved on: 
Monday, October 16, 2023
Pembrolizumab, Ipilimumab, AACR, Activity, NCNA, Melanoma, Immunotherapy, Nivolumab, Patient, Neoplasm, Conference, PD-1, Pharmaceutical industry, Medical imaging

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 that took place October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • NUC-7738 has been well tolerated both as a monotherapy and in combination with pembrolizumab.
  • This finding provides a rationale as to why NUC-7738 plus pembrolizumab may be effective in patients who have progressed on prior immunotherapy.
  • The patient biopsy data indicate that NUC-7738 may make tumors sensitive to treatment with immunotherapy, including anti-PD-1 agents.
  • We look forward to sharing additional updates as these data continue to mature.”

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

Retrieved on: 
Monday, October 9, 2023
NSCLC, Ipilimumab, United Kingdom, Bristol Myers Squibb, BMS, Medicine, Eli Lilly, Heart failure, Nivolumab, Marketing, Paclitaxel, Head, Boehringer Ingelheim, Denmark, Pharmaceutical industry, Lexicon

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.
  • During his time at BMS, Mr. Garner held a broad array of roles throughout BMS’ commercial organization including positions at local, country, and global levels, and across a diverse range of brands and therapeutic areas.
  • In his most recent role, Mr. Garner was the senior vice president and head of the U.S. Cardiovascular and Established Brands business unit, the single largest business unit across the BMS enterprise with reported total revenues in excess of $10 billion.
  • “We are very excited that Mr. Garner is joining Lexicon as our chief commercial officer,” said Lonnel Coats, Lexicon’s chief executive officer.

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Retrieved on: 
Friday, October 6, 2023
Neoplasm, NETS, Survival, Tumor microenvironment, Drug resistance, CM24, AACR, CEACAM1, PDAC, Lymphocyte, Biomarker, American Association for Cancer Research, Neutrophil extracellular traps, Mall of America, Poster, Pancreatic cancer, Cancer, Nivolumab, NET, Escape Room, SOC, Conference, Serum, Neutrophil, Pharmaceutical industry, Medical imaging, Vaccine, Patient

The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.

Key Points: 
  • The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.
  • “These encouraging data, demonstrating increased survival of PDAC patients whose biopsies show higher CEACAM1-positive lymphocytes, are consistent with the CM24 Mechanism of Action (MoA) in suppressing the immune evasion and suggest CEACAM1 expressing lymphocytes as a potential biomarker for CM24 therapy” said Purple Biotech VP R&D, Dr. Hadas Reuveni.
  • “NETs and CEACAM1 will continue to be monitored and investigated in our ongoing randomized Phase 2 study of CM24 in pancreatic cancer patients,” stated Purple Biotech CEO, Gil Efron.
  • “We look forward to reporting data from this study in the near term.”

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023
Clinical Science (journal), Ludwig Maximilian University of Munich, Cancer, Dana–Farber Cancer Institute, Department of Medicine – University of Pamplona, Faculty, Research, Clinical, Therapy, Case Western Reserve University, Hospital, Nature, Melanoma, Journal, Nivolumab, Carcinoma, Brigham and Women's Hospital, Harvard Medical School, Clinical trial, Associate, American Journal of Clinical Oncology, Principal investigator, Neoplasm, Patient, Vaccine, Pharmaceutical industry, New York University, Medicine

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Retrieved on: 
Sunday, October 15, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Congress, Phagocytosis, Tumor microenvironment, Hepatocellular carcinoma, NSCLC, Safety, Lung cancer, Interim, Grenfell Tower Inquiry Phase 2, Cancer, ESMO, MHC-II, Nivolumab, Nature Communications, Bladder cancer, European Society for Medical Oncology, ASCO, Neoplasm, Macrophage, Cytokine, Antigen, Chemokine, HCC, Patient, Oxidative stress, Vaccine

CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.

Key Points: 
  • CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.
  • The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages.
  • These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
  • Overall, the results indicate that GDF-15 counteracts myeloid immune cell activation, supporting the generation of an immune-evasive tumor microenvironment, an important feature in therapy resistance.

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

Retrieved on: 
Wednesday, October 11, 2023
Oncology, Health, Health Technology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PPF (company), EudraCT, Cancer, GEJ, Pancreatic cancer, NAB, Nivolumab, Safety, Patient, Pharmaceutical industry

CLAUDIO-01 is evaluating SOTIO’s potent antibody-drug conjugate SOT102 in patients with gastric and pancreatic cancer.

Key Points: 
  • CLAUDIO-01 is evaluating SOTIO’s potent antibody-drug conjugate SOT102 in patients with gastric and pancreatic cancer.
  • The combination arms will be the first clinical evaluation of SOT102’s potential as a first-line cancer treatment in combination with current standard of care.
  • In the gastric cancer arm, SOT102 will be combined with mFOLFOX plus nivolumab.
  • In the trial’s combination arm, by contrast, SOT102 will be dosed in combination with standard-of-care as a first-line treatment for patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) or pancreatic cancers.

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Congress, Lung cancer, NYSE, Bristol Myers Squibb, Research, NSCLC, PD-L1, Survival, Cancer, NTRK, ESMO, Melanoma, Immunotherapy, IIA, Checkmate, PFS, Bladder cancer, Metastasis, European Society for Medical Oncology, Progression-free survival, BMY, PD-1, Patient, Pharmaceutical industry, Medical imaging, Nivolumab/relatlimab, Nivolumab

Data from the Phase 3 CheckMate -901 and CheckMate -77T studies have been selected for presentation in Presidential Symposium sessions.

Key Points: 
  • Data from the Phase 3 CheckMate -901 and CheckMate -77T studies have been selected for presentation in Presidential Symposium sessions.
  • Data to be presented support the role of Opdivo and Opdivo-based combinations in both earlier and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.
  • , executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb.
  • Additional CheckMate -816 results will also be presented showing efficacy benefits with Opdivo plus Yervoy in resectable NSCLC.